Presentation Preview
People with Parkinson’s disease or parkinsonian conditions suffer from a range of symptoms, the most apparent of which may be motor impairment. However, efforts to explore meaningfulness to patients have resulted in recent drug development efforts also seeking to address non-motor symptoms. In Parkinson’s Disease, Parkinson’s disease Dementia (PDD), and parkinsonian disorders such as Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Dementia with Lewy Bodies (DLB), it is important to evaluate the impact of a range of symptom domains—including cognitive or behavioral impairment—and to understand how these may relate to motor symptoms.
To better answer important questions about the safety and efficacy of therapeutic candidates for people with Parkinson’s disease and atypical Parkinsonian disorders, fit-for-purpose assessments are critical to evaluate the full range of symptom domains to gather a complete picture of an individual’s condition.
In this webinar, scientists from Clario and Cogstate offer guidance on effective digital and conventional assessment options, tactics to improve the quality of data via strategic rater training and monitoring, and describe how to leverage precision motion sensor technology to discover meaningful and functional insights on patient motor function. The discussion includes regulatory considerations, such as acceptance, recent DHT guidance, and approval pathway selection for COA or biomarker endpoints.
VIEWERS WILL LEARN:
- How to select and manage fit-for-purpose digital and conventional assessment options.
- Options to improve the quality of data captured via strategic rater training and monitoring.
- How to leverage precision motion sensor technology to discover meaningful and functional insights on patient motor function.
Speakers
Chris Edgar, PhD
Chief Science Officer, Cogstate
Lisle Kingery, PhD
Senior Principal Scientist, Cogstate
Kristen Sowalsky, DC, PhD
VP Medical & Scientific Affairs, Precision Motion, Clario
